Evidence map›Paper›PMID 40786663›Full record

ArticlePRX life

Frequency-Dependent Ecological Interactions Increase the Prevalence, and Shape the Distribution, of Preexisting Drug Resistance.

Jeff Maltas, Dagim Shiferaw Tadele, Arda Durmaz, Christopher D McFarland, Michael Hinczewski, Jacob G Scott

Abstract read
In one paragraph

Article in PRX life. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Stochastic Evolutionary Control in Heterogeneous Populations.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cell-cell fusion in cancer: The next cancer hallmark?The international journal of biochemistry & cell biology · 2024
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Jeff MaltasCleveland Clinic, Translational Hematology Oncology Research, Cleveland, Ohio 44195, USA.ORCID 0000-0001-6567-6800
Dagim Shiferaw TadeleCleveland Clinic, Translational Hematology Oncology Research, Cleveland, Ohio 44195, USA.ORCID 0000-0001-8319-678X
Arda DurmazCleveland Clinic, Translational Hematology Oncology Research, Cleveland, Ohio 44195, USA.ORCID 0000-0001-8394-600X
Christopher D McFarlandCase Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA.ORCID 0000-0002-6901-4035
Michael HinczewskiCase Western Reserve University, Department of Physics, Cleveland, Ohio 44106, USA.ORCID 0000-0003-2837-7697
Jacob G ScottCleveland Clinic, Translational Hematology Oncology Research, Cleveland, Ohio 44195, USA.ORCID 0000-0003-2971-7673

Funding

Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung CancerR37CA244613 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Jacob Gardinier Scott · 2020 to 2026
$4.0M
Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modelingU01CA280829 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Andriy Marusyk, Jacob Gardinier Scott · 2023 to 2026
$2.6M
Computational Genomic Epidemiology of Cancer (CoGEC) Training ProgramT32CA094186 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Thomas Louis LaFramboise, Rong Xu · 2017 to 2026
$2.6M
NCI NIH HHS R37 CA244613NCI NIH HHS T32 CA094186NCI NIH HHS U01 CA280829
6 · The paper itself

Abstract

The evolution of resistance remains one of the primary challenges for modern medicine, from infectious diseases to cancers. Many of these resistance-conferring mutations often carry a substantial fitness cost in the absence of treatment. As a result, we would expect these mutants to undergo purifying selection and be rapidly driven to extinction. Nevertheless, preexisting resistance is frequently observed from drug-resistant malaria to targeted cancer therapies in non-small-cell lung cancer (NSCLC) and melanoma. Solutions to this apparent paradox have taken several forms, from spatial rescue to simple mutation supply arguments. Recently, in an evolved resistant NSCLC cell line, we found that frequency-dependent ecological interactions between ancestor and resistant mutant ameliorate the cost of resistance in the absence of treatment. Here, we hypothesize that frequency-dependent ecological interactions in general play a major role in the prevalence of preexisting resistance. We combine numerical simulations with robust analytical approximations to provide a rigorous mathematical framework for studying the effects of frequency-dependent ecological interactions on the evolutionary dynamics of preexisting resistance. First, we find that ecological interactions significantly expand the parameter regime under which we expect to observe preexisting resistance. Next, even when positive ecological interactions between mutants and ancestors are rare, these resistant clones provide the primary mode of evolved resistance because even weak positive interaction leads to significantly longer extinction times. We then find that even in the case where mutation supply alone is sufficient to predict preexisting resistance, frequency-dependent ecological forces still contribute a strong evolutionary pressure that selects for increasingly positive ecological effects (negative frequency-dependent selection). Finally, we genetically engineer several of the most common clinically observed resistance mechanisms to targeted therapies in NSCLC, a treatment notorious for preexisting resistance. We find that each engineered mutant displays a positive ecological interaction with their ancestor. As a whole, these results suggest that frequency-dependent ecological effects can play a crucial role in shaping the evolutionary dynamics of preexisting resistance.

Identifiers

PMID40786663
PMCPMC12333505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.